The Drugs to Watch at ASCO in 2024

As part of our Drugs to Watch program, Clarivate oncology experts pored over the 5,000-plus abstracts submitted to the ASCO Annual Meeting to identify ten particularly striking results, along with an additional five of import to the fast-growing Mainland China market, laying out the context, key findings and potential market impact of each.

This year’s ASCO Drugs to Watch include:

TAGRISSO after chemoradiotherapy in EGFR-mutated unresectable stage III NSCLC
Imfinzi in limited-stage SCLC after concurrent chemoradiation
Neoadjuvant OPDIVO® plus YERVOY® in resectable stage III malignant melanoma
ENHERTU® after endocrine therapy in hormone receptor-positive, HER2-low and HER2-ultralow breast cancer
VERZENIO® plus fulvestrant in HR+, HER2-negative breast cancer patients with disease progression on CDK4/6 inhibitors
OPDIVO® plus YERVOY® in first-line advanced hepatocellular carcinoma
Lumakras plus Vectibix in pretreated KRAS G12C-mutated metastatic colorectal cancer
BLENREP® in relapsed or refractory (R/R) multiple myeloma
Adcetris plus lenalidomide and rituximab in heavily pretreated DLBCL
SCEMBLIX® in newly diagnosed chronic phase CML

And for Mainland China:

EPIDAZA® in de novo DLBCL
Four new KRAS G12C inhibitors in the treatment of KRAS-mutated unresectable NSCLC
Suvemcitug in platinum-resistant ovarian cancer regardless of prior drug use
Sacituzumab tirumotecan in heavily pretreated metastatic triple-negative breast cancer
AIRUIEN® plus docetaxel in metastatic castrate-resistant prostate cancer